Haleon Corp (HLN): Price-to-Projected Revenue Ratio

haleon.com (HLN) - corporate logo

Haleon plc is investing in R&D and digital diagnostics to strengthen its scientific potential. The organization's forward P/S visualizes market expectations, while 2.20 reflects the metric's latest value. Revenues depend on seasonality and brand loyalty. A steady cash flow allows the company to effectively reduce its debt load, ensuring high financial stability.

Haleon - HLN Market Cap to Future Revenue Ratio (period 04/28/2023 - 11/15/2026)

Haleon - analytical breakdowns and key metrics (HLN)

- current price and projected stock value:
- stock exchange capitalization data:
Summary company analysis:HLN (Haleon)
Original product of haleon.com

The forward P/S ratio compares the current market capitalization of Haleon plc (HLN) with expected revenue, determining the premium for future sales. This metric is sensitive to the company's ability to pass inflation onto consumers due to the inelastic demand for the Sensodyne and Panadol brands. Analyzing the expected P/S metric allows for an objective valuation of the business, eliminating time lags and protecting investors from trading at emotional extremes.

Direct competitors

Price-to-Projected Revenue Ratio Kenvue Inc KVUE|Verona Pharma Corp - Price-to-Projected Revenue Ratio|MENS: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Ligand Pharmaceuticals LGND|Amneal Pharmaceuticals Inc (AMRX) - Price-to-Projected Revenue Ratio|Perrigo Company PLC - Forward Price to Sales|Price-to-Projected Revenue Ratio alvotech.com|Forward P/S Multiple Liquidia Technologies|Price-to-Projected Revenue Ratio Galapagos Genomics (GLPG)|ANIP: Future Price to Revenue|Forward P/S Multiple MNKD (MannKind Corp)|Market Cap to Expected Sales Ratio Amphastar (AMPH)|PCRX: Forward Price-to-Revenue Multiple|SPRY - Forward P/S Multiple|Theravance Biopharma, Inc. (TBPH) - Price-to-Projected Revenue Ratio|AQST (Aquestive Therapeutics) - Price-to-Projected Revenue Ratio|SCPH (scpharmaceuticals.com) - Forward P/S Multiple|TECX: Forward Price to Sales|Price-to-Projected Revenue Ratio Tonix Pharmaceuticals Inc. (TNXP)|SXTC (SXT Pharmaceuticals) - Forward Price to Sales|Forward P/S Multiple EPRX (Eupraxia Pharmaceuticals)|Forward Price to Sales BHST|Invizyne Technologies - Forward P/S Multiple|oramed.com (ORMP) - Forward Price-to-Revenue Multiple|ENTX (enterabio.com) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue HYFT|ABVC (ABVC BioPharma, Inc) - Forward P/S Multiple|Forward P/S Multiple cumberlandpharma.com|Price-to-Projected Revenue Ratio Quantum BioPharma (QNTM)|FibroGen (FGEN) - Projected Price to Revenue|Forward P/S Multiple TELO (telomirpharma.com)|RANI - Forward Price-to-Revenue Multiple|SNYR - Price-to-Projected Revenue Ratio|rallybio.com - Price to Expected Revenue Ratio|LEXX: Forward P/S Multiple|Forward Price-to-Revenue Multiple Pulmatrix Inc|PTHL (Pheton Holdings) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Aptorum Group Limited APM|Price-to-Projected Revenue Ratio Lyra Therapeutics (LYRA)|Forward Price-to-Revenue Multiple Impact BioMedical Inc IBO|Price-to-Projected Revenue Ratio tnfpharma.com TNFA|Forward Price to Sales YCBD|PainReform Ltd - Forward P/S Multiple|Altamira Therapeutics Ltd (CYTO) - Forward Price-to-Revenue Multiple|lipella.com (LIPO) - Price-to-Projected Revenue Ratio|OptiNose (OPTN) - Forward P/S Multiple|PIRS (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|PROC: Forward Price to Sales|Price-to-Projected Revenue Ratio Petros Pharmaceuticals, Inc. (PTPI)|Forward P/S Multiple Qilian International Corp (QLI)|ACELYRIN, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple tffpharma.com TFFP